Dr. Hwa Mu Lee is Clinical Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of California, Irvine College of Medicine, in Irvine, California and Clinical Professor of Medicine at Western University of Health Sciences, in Pomona, California, and is Chairman of the Dept. of Medicine at West Anaheim Medical Center in Anaheim, California

Dr. Lee is a noted authority on the relation of COPD with cardiovascular disease, including the role of cardiovascular risk assessment in patients with COPD and the role of lung function in the prediction of cardiovascular outcomes.

Dr.Yong-Xiao Wang has been a Full Professor in Albany Medical College (USA) since 2006.Dr. Wang has had extensive research experience in basic,translational and drug research concerning pulmonary hypertension, asthma, chronic obstructive pulmonary disease, diabetes, and cardiac arrhythmia for over 30 years. As the Principal Investigator, he has/had numerous NIH R01 research awards, AHA Established Investigator Award, and various other grants, for which he often holds/held 2 – 3 NIH R01 grants with other awards each year. As the corresponding author, first author and key contributor, he has had numerous publications in highly peer-reviewed journals including Antioxid Redox Signal (impact factor: 8.209), Proc Natl Acad Sci USA (9.432), Nature (34.480), Circ Res (9.214), etc. Dr. Wang has been the editor of academic books in the field including one entitled by “Redox Signaling in Health and Disease Pulmonary Vasculature” that has been confirmed for publication by Springer (New York). Dr. Wang has also served as the editorial board member and/or section editor for the Clinical and Translational Medicine, Pulmonary Circulation and several other journals.

Pulmonary hypertension, Asthma, Chronic obstructive pulmonary disease

Within his academic training, he is a RRT-Respiratory Therapist graduated from Santa Paula University, and holds a master's degree in integral health and human movement / emphasis in graduate health at the National University of Costa Rica, in addition to completing the course of Cardiopulmonary Rehabilitation phase II in The National University of Costa Rica, and performed the certification of pediatric and neonatal critical air transport of the Asturian association of pediatric intensive care. He works in the Costa Rican social insurance fund from 2000 to the present, in 2005 until 2008 he worked in clinical research at the ICIC, during this same period also work in home care program for patients with COPD from 2013 to 2016 was coordinator of the cardiopulmonary rehabilitation center at the Adolfo Carit Eva Women's Hospital and from 2015 to date The director of the Santa Paula cardiopulmonary rehabilitation center at Santa Paula Clinic.

COPD

He is a President, International Biophilia Rehabilitation Academy and is a Professor at Biophilia Institute,The Designated and Registered Institute by the Japanese Ministry of Education, Culture, Sports, Science and Technology

Neural Stem cell,Rehabilitation

Dr. Yong-Xiao Wang has been a Full Professor in Albany Medical College (USA) since 2006. Dr. Wang has had extensive research experience in basic, translational and drug research concerning pulmonary hypertension, asthma, chronic obstructive pulmonary disease, diabetes, and cardiac arrhythmia for over 30 years. As the Principal Investigator, he has/had numerous NIH R01 research awards, AHA Established Investigator Award, and various other grants, for which he often holds/held 2 – 3 NIH R01 grants with other awards each year. As the corresponding author, first author and key contributor, he has had numerous publications in highly peer-reviewed journals including Antioxid Redox Signal (impact factor: 8.209), Proc Natl Acad Sci USA (9.432), Nature (34.480), Circ Res (9.214), etc. Dr. Wang has been the editor of academic books in the field including one entitled by “Redox Signaling in Health and Disease Pulmonary Vasculature” that has been confirmed for publication by Springer (New York). Dr. Wang has also served as the editorial board member and/or section editor for the Clinical and Translational Medicine, Pulmonary Circulation and several other journals.

Pulmonary hypertension, Asthma, Chronic Obstructive Pulmonary Disease, Diabetes, and Cardiac Arrhythmia

Dr.Ohta graduated from the Univ of Tokyo School of Medicine in 1975, and had been Prof of Medicine at Teikyo Univ Schl of Med for 15 years until March in 2012. He has been President at National Hospital Organization Tokyo National Hospital since April in 2012. His speciality is pulmonary medicine and allergology as well as internal medicine. He still teachs at Teikyo Univ as a visiting professor. He has been interested in asthma, interstitial lung diseases and COPD. He has studied in US from 1980 to 1983 on IgE regulation and from 1988 and 1989 on idiopathic pulmonary fibrosis, both at the National Jewish Health in Denver. He has been involved in producing Japanese Guidelines for asthma as a chairman of the committee belonging to Japanese Society of Allergology since 2004. He had been a member of the Board of Directors and the Science Committee for GINA (Global Initiative for Asthma) for 10 years until 2012. He is a member of AAAAI (American Academy of Allergy Asthma and Immunology) and ACCP (American College of Chest Physicians) as Fellow (FAAAAI and FCCP, respectively). He is one of Members at Large for INTERASMA and a member of the Executive Committee for ARIA (Allergic Rhinitis and its Impact on Asthma).

asthma, interstitial lung diseases and COPD

Hiroaki Kume obtained his MD from Toyama Medical and Pharmaceutical University in 1982. He has completed his PhD in Department of Medicine (II), Nagoya University School of Medicine in 1990, and postdoctoral studies from School of Veterinary Medicine, University of Pennsylvania (Dr. Michael I. Kotlikoff’s Lab). Currently, he works at Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine and Department of Respiratory Medicine, Rinku General Medical Center, Izumisano City, Osaka 598-8577, Japan, and focuses on investigating the characteristics of COPD with the goal of rational therapy for COPD

COPD Asthma

Nobuaki Miyahara graduated from Hiroshima University School of Medicine in 1988. He has completed his PhD in Department of Medicine II, Okayama University School of Medicine in 1994. He had done research on allergic airway inflammation at the National Jewish Health in Denver, CO, USA (Dr. Erwin Gelfand’s Lab) from 2001 to 2008. Currently, he works at Department of Medical Technology, Okayama University Graduate School of Health Sciences, and Department of Allergy and Respiratory Medicine, Okayama University Hospital.

COPD Asthma

Amnon Ariel is the immediate past president of the Israel Society of Pulmonology, and current lead of Clalit Heathcare Services COPD program. He is currently involved in clinical and organizational endeavors of improving airway disease diagnosis management and related database research in Clalit Healthcare Services (insuring 55 percent of the population in Israel). He is co-author of the 2004 Canadian COPD Guidelines and the 2017 Israeli Position Paper of the diagnosis and management of COPD in the community.

COPD

Mohamed Eddouks is Professor at Moulay Ismail University, Faculty of Sciences and Techniques Errachidia, Morocco. He is a researcher in Physiology and Pharmacology with a Master Degree in Metabolic and Molecular Endocrinology from University of Paris vi, a specialized certificate in Endocrine Pharmacology from University of Paris vii and PhD degrees in Physiology and Pharmacology from University of Liege, Belgium and Sidi Mohammed Ben Abdellah University, Fez, Morocco. After his post-doctoral fellowship at Department of Physiology, Faculty of Medicine of Montreal, Canada, he is working for the last 16 years on medicinal plants. His work on antidiabetic and antihypertensive plants is well recognized globally. His research focuses on ethnobiological as well as pharmacological issues in the use of Moroccan medicinal plants for the treatment of diabetes mellitus, obesity and hypertension. His contribution to this field includes four international books and more than 80 peer-reviewed articles and book chapters of international repute. He is Guest Editor of American Journal of Pharmacology and Toxicology, Lead Guest Editor of an annual special issue published by Evidence-Based and Complementary Alternative Medicine, Regional Editor of the Following journals: American Journal of Food Technology, Journal of Applied Sciences, Trends in Applied Sciences Research and Singapore Journal of Scientific research, Member of Editorial Board of several international journals. He has been honored with the first Prize of Scientific Research in 2008 by the Moroccan Association of Research and Development and the first Prize of the Federation of Arab Scientific Councils in 2016. He has been the Dean of Polydisciplinary Faculty of Errachidia from 2008 to 2012.

Phytotherapy. Ethnopharmacology

Prof. Ping Yang has completed her MD from Beijing Medical College in China and PhD at Johns Hopkins University in USA. She has been leading a comprehesive lung cancer research program at Mayo Clinic since 1997, emphasizing patient-centered outcome research with COPD as one of the key interaested areas. She has published more than 200 peer-reviewed papers and has been serving as an editorial board member of Jounal of Clinical Oncology and Associate Editir of Journal of Thoracic Oncology.

Thoracic oncology, COPD Realted to Cancer

Tsukasa Kadota graduated from Jikei University School of Medicine where he also completed his residency in pulmonary medicine. He is a research associate at The Jikei University School of Medicine and a visiting scientist at National Cancer Center Research Institute.

Pulmonary disease, COPD, Respiratory

Joaquim Gea obtained his MD (1979) and PhD (1989) degrees at the Universitat de Barcelona, being specialist in both Internal Medicine (1981) and Respiratory Medicine (1985). He is the Head of the Respiratory Department at Hospital del Mar, Full Professor and Dean of the School of Medicine at Universitat Pompeu Fabra and Deputy Director at the Spanish Network of Excellence for Research in Respiratory Diseases (CIBERES). He has been funded by 65 competitive grants, including 4 projects funded by the European Commission, and published more than 260 Original Articles and Reviews in peer reviewed journals as well as 50 book chapters.

COPD, Respiratory Diseases

Dr. Patrick Vanscheeuwijck is Director pre-clinical toxicology at Philip Morris International, Reduced Risk Products, and Switzerland, responsible for the in vitro and in vivo assessment of Reduced Risk Products (RRPs). The focus of his career at PMI has been on the development of approaches for the assessment of hazard associated with cigarette smoke and aerosols from RRPs, inhalation toxicology and animal models of disease; with more than 30 peer-reviewed publications. He has a Ph.D. in biochemical pharmacology (University of Gent, Belgium), performed postdocs at the University of Arizona, U.S. and the University of Leuven, Belgium in molecular pharmacology and molecular biology.

COPD, Emphysema, Toxicology

Director in Respiratory care

lot of work around COPD management and controlling prevention of exacerbations

Reearch in Inferctious Diseases

Drug discovery and drug screening to combat infectious diseases.

Lead of the global Allergy and Respiratory Team in Medical Services; and currently he is Senior Medical Director and Chair of the Allergy and Respiratory Center of Excellence.

He is experienced in global product management and life cycle developments. Before joining Quintiles, he was the medical lead for three compounds currently marketed.

More than 190 publications in international journals, transactions and proceedings in the areas of Modelling, Biomechanical Engineering, System Dynamics and Controls, Vibration of Structures, and Mechanical Design. Chairing and organising more than 32 symposiums

Respiratory System Dynamics Cardiovascular System Dynamics

experience as a teacher, researcher and clinician over 35 years.He has been the President and office bearer of a couple of scientific bodies and is associated with a number of scientific journals.

Pulmonary Medicine, COPD